Latest Insider Transactions at Tricida, Inc. (TCDA)
This section provides a real-time view of insider transactions for Tricida, Inc. (TCDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Tricida, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Tricida, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
34,366
+0.48%
|
$309,294
$9.71 P/Share
|
|
Jun 24
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
149,120
+2.07%
|
$1,342,080
$9.68 P/Share
|
|
Jun 23
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+2.81%
|
$2,000,000
$10.5 P/Share
|
|
Jun 22
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
142,900
+2.08%
|
$1,429,000
$10.9 P/Share
|
|
Jun 16
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
5,951
+0.09%
|
$53,559
$9.69 P/Share
|
|
Jun 14
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.15%
|
$80,000
$8.72 P/Share
|
|
Jun 13
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
50,000
+0.76%
|
$400,000
$8.14 P/Share
|
|
Jun 10
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
58,054
+0.88%
|
$464,432
$8.91 P/Share
|
|
Jun 09
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
109,100
+1.66%
|
$872,800
$8.97 P/Share
|
|
Jun 08
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
111,111
+1.72%
|
$999,999
$9.51 P/Share
|
|
Jun 07
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
367,813
+5.57%
|
$3,310,317
$9.89 P/Share
|
|
Jun 06
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
91,506
+1.54%
|
$823,554
$9.35 P/Share
|
|
Jun 03
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
37,643
+0.65%
|
$338,787
$9.33 P/Share
|
|
Jun 02
2022
|
Venrock Healthcare Capital Partners Ii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
61,722
+1.06%
|
$493,776
$8.78 P/Share
|
|
Apr 28
2022
|
Brian M. Isern > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
11,804
-0.22%
|
$118,040
$10.61 P/Share
|
|
Apr 27
2022
|
Brian M. Isern > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
33,569
-0.63%
|
$335,690
$10.97 P/Share
|
|
Apr 26
2022
|
Brian M. Isern > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
726
-0.01%
|
$7,986
$11.9 P/Share
|
|
Mar 22
2022
|
Sandra I Coufal Director |
SELL
Other acquisition or disposition
|
Indirect |
6,423,493
-100.0%
|
-
|
|
Dec 31
2021
|
Gerrit Klaerner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,767
-0.75%
|
$24,903
$9.56 P/Share
|
|
Dec 31
2021
|
Geoffrey M. Parker COO, CFO and EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
1,384
-2.13%
|
$12,456
$9.56 P/Share
|
|
Dec 31
2021
|
Dawn Parsell Otto EVP, Clinical Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,574
-31.24%
|
$14,166
$9.56 P/Share
|
|
Dec 31
2021
|
Wilhelm Stahl EVP, Chief Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,384
-6.0%
|
$12,456
$9.56 P/Share
|
|
Dec 31
2021
|
Robert Mc Kague EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,384
-15.21%
|
$12,456
$9.56 P/Share
|
|
Dec 20
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
7,500
-7.04%
|
$60,000
$8.54 P/Share
|
|
Dec 16
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
931
-0.87%
|
$7,448
$8.38 P/Share
|
|
Dec 15
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
2,550
-2.32%
|
$20,400
$8.01 P/Share
|
|
Dec 14
2021
|
Wilhelm Stahl EVP, Chief Tech Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
576
-2.44%
|
$4,032
$7.7 P/Share
|
|
Dec 14
2021
|
Wilhelm Stahl EVP, Chief Tech Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,664
+6.58%
|
-
|
|
Dec 08
2021
|
Gerrit Klaerner President and CEO |
SELL
Open market or private sale
|
Direct |
8,000
-2.12%
|
$56,000
$7.84 P/Share
|
|
Dec 08
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
500
-0.45%
|
$4,000
$8.0 P/Share
|
|
Dec 07
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
15,722
-12.46%
|
$125,776
$8.03 P/Share
|
|
Dec 01
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
1,600
-1.25%
|
$12,800
$8.02 P/Share
|
|
Nov 18
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
800
-0.62%
|
$5,600
$7.72 P/Share
|
|
Nov 17
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
10,297
-7.41%
|
$72,079
$7.9 P/Share
|
|
Nov 15
2021
|
David P Bonita Director |
BUY
Grant, award, or other acquisition
|
Indirect |
666,667
+6.09%
|
$4,000,002
$6.0 P/Share
|
|
Nov 15
2021
|
Geoffrey M. Parker COO, CFO and EVP |
BUY
Grant, award, or other acquisition
|
Indirect |
166,667
+38.91%
|
$1,000,002
$6.0 P/Share
|
|
Nov 15
2021
|
Gerrit Klaerner President and CEO |
SELL
Open market or private sale
|
Direct |
126,000
-25.08%
|
$756,000
$6.02 P/Share
|
|
Nov 15
2021
|
Orbimed Advisors LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
666,667
+6.09%
|
$4,000,002
$6.0 P/Share
|
|
Oct 06
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
5,000
-3.47%
|
$20,000
$4.22 P/Share
|
|
Sep 10
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
5,000
-3.36%
|
$20,000
$4.23 P/Share
|
|
Aug 24
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
1,354
-0.9%
|
$5,416
$4.01 P/Share
|
|
Aug 20
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
546
-0.36%
|
$1,638
$3.87 P/Share
|
|
Aug 19
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
3,100
-2.01%
|
$9,300
$3.96 P/Share
|
|
Jul 20
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
2,500
-1.6%
|
$10,000
$4.02 P/Share
|
|
Jul 15
2021
|
Sandra I Coufal Director |
SELL
Open market or private sale
|
Direct |
2,500
-1.57%
|
$7,500
$3.76 P/Share
|
|
Jun 10
2021
|
Robert J Alpern Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,403
+9.33%
|
-
|
|
Jun 10
2021
|
Kathryn E Falberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,403
+21.71%
|
-
|
|
Jun 10
2021
|
Klaus R Dr Veitinger Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,403
+37.29%
|
-
|
|
Jun 10
2021
|
Sandra I Coufal Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,403
+9.36%
|
-
|
|
Jun 10
2021
|
David P Bonita Director |
BUY
Grant, award, or other acquisition
|
Indirect |
16,403
+37.29%
|
-
|